SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-Hodgkin's lymphoma (NHL); mantle cell lymphoma (MCL)	Histone deacetylase 6 (HDAC6); microRNA-548m (miR-548m); c-Myc (MYC)	*In vitro* and mouse studies suggest inhibiting HDAC6 and MYC could help treat MCL and other NHLs. In MCL or other lymphoma cells cocultured with stromal cells, overexpression of miR-548m or inhibition of its target, HDAC6, prevented stromal adhesion–induced resistance to mitoxantrone chemotherapy. In mouse xenograft models of lymphoma, inhibiting MYC using the reagent JQ1 plus mitoxantrone or an HDAC6 inhibitor was more effective than single agents. Next steps could include testing the combination therapy in animal models of additional types of NHL. Acetylon Pharmaceuticals Inc. has the HDAC6 inhibitor ACY-1215 in Phase I/II testing to treat multiple myeloma (MM). At least two other companies have HDAC6 inhibitors in preclinical testing. *SciBX* 6(43); doi:10.1038/scibx.2013.1221 Published online Nov. 7, 2013	Patent and licensing status unavailable	Lwin, T. *et al. J. Clin. Invest.*; published online Oct. 8, 2013; doi:10.1172/JCI64210 **Contact:** Jianguo Tao, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. e-mail: jianguo.tao@moffitt.org